CJC-1295 / Ipamorelin
Blend GHRH + GHRP (Mod GRF 1-29 + Ipamorelin)
This blend combines, in a single vial, CJC-1295 (without DAC / Mod GRF 1-29), a GHRH analog, and Ipamorelin, a ghrelin-mimetic GHRP. The two peptides act on distinct but complementary pituitary receptors: their combination is the reference stack for amplifying the body's natural growth hormone (GH) pulse while respecting physiological pulsatility. Sought after for recovery, deep sleep, and optimizing body composition. The 20 mg vial contains a 1:1 blend (roughly 10 mg of each peptide).
Potential benefits
Amplified GH pulse
GHRH (CJC-1295) and GHRP (Ipamorelin) act synergistically to amplify GH release.
Deep sleep
Promotes deeper sleep, a key phase for nighttime GH secretion.
Recovery
Supports tissue repair and post-exercise recovery.
Body composition
Via increased IGF-1, helps preserve lean mass and mobilize fat.
Respected pulsatility
The short duration of action limits receptor saturation and preserves the natural GH rhythm.
Convenience
A single vial and a single injection for the GHRH + GHRP combination.
Mechanism of action
- CJC-1295 (without DAC) binds to GHRH receptors on the pituitary gland to trigger a pulse of GH secretion.
- Ipamorelin stimulates ghrelin receptors (GHS-R), a complementary pathway that amplifies this pulse.
- The dual stimulation (GHRH + GHRP) produces a GH response greater than either peptide alone.
- Secondary rise in IGF-1, a mediator of regeneration and protein synthesis.
- Selective profile: Ipamorelin does not significantly raise cortisol, prolactin, or appetite.
Evolution over time
Often deeper sleep, a sense of better recovery.
Faster muscle recovery, more stable energy, reduced soreness.
Progressive optimization of body composition and tissue regeneration.
Established benefits for recovery and vitality, more lasting results.
Dosages & protocol
Reference dosages
12 wk + 4 off
Fasted, before bedtime (and/or around training), 1 to 2 times per day
Varies by component: CJC-1295 without DAC (Mod GRF 1-29) has a short half-life (~30 min), ipamorelin about 2 h; together they produce a brief GH pulse that preserves physiological pulsatility.
Why combine GHRH and GHRP?
GHRH (CJC-1295) and GHRP (Ipamorelin) stimulate GH through two different pathways. Combining them produces a stronger, sharper GH pulse than either peptide alone.
- CJC-1295 (without DAC): triggers the pulse via the GHRH receptor.
- Ipamorelin: amplifies this pulse via the ghrelin receptor, without a marked effect on cortisol or appetite.
- Result: synergistic GH response while respecting natural pulsatility.
Recommended dilution (20 mg 1:1 vial, U-100 syringe)
- 2 mL of BAC → 10 mg/mL of blend (roughly ~5 mg/mL of each peptide) → 100 mcg of each per unit.
- 4 mL of BAC → 5 mg/mL of blend → 50 mcg of each per unit, larger injection volume.
- Example: 200 mcg of each peptide = 2 units at 2 mL, or 4 units at 4 mL.
- Inject fasted, preferably before bedtime, to maximize the nighttime GH peak.
Usage tips
- Inject fasted: an insulin or carbohydrate spike blunts the GH response.
- Prefer dosing before bedtime to align with the nighttime GH peak.
- Wait 20-30 minutes before eating after the injection.
- Start low, go slow, and maintain good sleep hygiene.
- Store in the refrigerator (2 – 8 °C), do not freeze; gently roll the vial.
Good to know / effects to watch
- Mild, transient water retention possible.
- Drowsiness or fatigue, especially after the evening injection.
- Hot flashes / flushing and transient tingling.
- Redness or local discomfort at the injection site.
- Pregnancy, breastfeeding, and a history of GH-sensitive tumors: caution advised; consult a healthcare professional if in doubt.
Storage
- Before reconstitution: lyophilized powder refrigerated (2-8 °C), protected from light.
- After reconstitution (bacteriostatic water): refrigerate (2-8 °C), protect from light; use within the following weeks.
- Do not freeze; swirl the vial gently, do not shake.
Contraindications
- Pregnancy and breastfeeding.
- Active cancer or history of a GH/IGF-1-sensitive tumor.
- Uncontrolled diabetes or marked insulin resistance (possible effect on blood glucose): caution.
- Active proliferative retinopathy.
- Known hypersensitivity to CJC-1295, ipamorelin or an excipient.
Possible synergistic combinations
The catalog peptides are clickable — to complete or optimize your protocol.
Promotes tissue regeneration and complements the recovery action.
View the sheet & add →Tissue repair and overall recovery in synergy.
View the sheet & add →Maximize body recomposition and metabolic health.
Sources & references
Links to external sources (scientific databases, trial registries, authorities). RAL Peptides is not responsible for their content.
⚠ For research use only. NOT intended for use on humans or animals. The values shown are indicative and for informational purposes ; each person reacts differently. This guide does not replace medical advice — consult a healthcare professional if in doubt.